Elevated global SUMOylation in Ubc9 transgenic mice protects their brains against focal cerebral ischemic damage

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Lee, Yang ja ^a   Mou, Yongshan ^a   Maric, Dragan ^a   Klimanis, Dace ^a   Auh, Sungyoung ^a   Hallenbeck, John M ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; GLUCOSE; OXYGEN; PROTEIN UBC9; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN CONJUGATING ENZYME UBC9; UBIQUITIN-CONJUGATING ENZYME UBC9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; BRAIN INFARCTION; BRAIN ISCHEMIA; CELL PROTECTION; CONJUGATION; CONTROLLED STUDY; FEMALE; GENOTYPE; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; SUMOYLATION; TRANSGENIC MOUSE; ANIMAL; BRAIN; CEREBRAL ARTERY DISEASE; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; STATISTICAL MODEL; TIME;

ANIMALIA; MUS; MUS MUSCULUS; SPERMOPHILUS;

ANIMALS; BRAIN; FEMALE; INFARCTION, MIDDLE CEREBRAL ARTERY; LINEAR MODELS; MALE; MICE; MICE, TRANSGENIC; PHENOTYPE; SUMOYLATION; TIME FACTORS; UBIQUITIN-CONJUGATING ENZYMES;

EID: 80053903500     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025852     Document Type: Article

References (40)

1. Mergenthaler P, Dirnagl U, Meisel A, (2004) Pathophysiology of stroke: lessons from animal models. Metab Brain Dis 19: 151-167.
2. Dirnagl U, Iadecola C, Moskowitz MA, (1999) Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22: 391-397.
3. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, et al. (2006) 1,026 experimental treatments in acute stroke. Ann Neurol 59: 467-477.
4. Hallenbeck JM, Frerichs KU, (1993) Stroke therapy. It may be time for an integrated approach. Arch Neurol 50: 768-770.
5. Frerichs KU, Hallenbeck JM, (1998) Hibernation in ground squirrels induces state and species-specific tolerance to hypoxia and aglycemia: an in vitro study in hippocampal slices. J Cereb Blood Flow Metab 18: 168-175.
6. Tempe D, Piechaczyk M, Bossis G, (2008) SUMO under stress. Biochem Soc Trans 36: 874-878.
7. Hay RT, (2005) SUMO: a history of modification. Mol Cell 18: 1-12.
8. Muller S, Hoege C, Pyrowolakis G, Jentsch S, (2001) SUMO, ubiquitin's mysterious cousin. Nat Rev Mol Cell Biol 2: 202-210.
9. Tatham MH, Jaffray E, Vaughan OA, Desterro JM, Botting CH, et al. (2001) Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1/SAE2 and Ubc9. J Biol Chem 276: 35368-35374.
10. Frerichs KU, Kennedy C, Sokoloff L, Hallenbeck JM, (1994) Local cerebral blood flow during hibernation, a model of natural tolerance to "cerebral ischemia". J Cereb Blood Flow Metab 14: 193-205.
11. Carey HV, Andrews MT, Martin SL, (2003) Mammalian hibernation: cellular and molecular responses to depressed metabolism and low temperature. Physiol Rev 83: 1153-1181.
12. Storey KB, (2003) Mammalian hibernation. Transcriptional and translational controls. Adv Exp Med Biol 543: 21-38.
13. Ginsberg MD, (2003) Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis Lecture. Stroke 34: 214-223.
14. Lee YJ, Miyake S, Wakita H, McMullen DC, Azuma Y, et al. (2007) Protein SUMOylation is massively increased in hibernation torpor and is critical for the cytoprotection provided by ischemic preconditioning and hypothermia in SHSY5Y cells. J Cereb Blood Flow Metab 27: 950-962.
15. Frerichs KU, Smith CB, Brenner M, DeGracia DJ, Krause GS, et al. (1998) Suppression of protein synthesis in brain during hibernation involves inhibition of protein initiation and elongation. Proc Natl Acad Sci U S A 95: 14511-14516.
16. Lee YJ, Castri P, Bembry J, Maric D, Auh S, et al. (2009) SUMOylation participates in induction of ischemic tolerance. J Neurochem 109: 257-267.
17. Yang W, Sheng H, Warner DS, Paschen W, (2008b) Transient global cerebral ischemia induces a massive increase in protein sumoylation. J Cereb Blood Flow Metab 28: 269-279.
18. Cimarosti H, Lindberg C, Bomholt SF, Ronn LC, Henley JM, (2008a) Increased protein SUMOylation following focal cerebral ischemia. Neuropharmacology 54: 280-289.
19. Yang W, Sheng H, Warner DS, Paschen W, (2008a) Transient focal cerebral ischemia induces a dramatic activation of small ubiquitin-like modifier conjugation. J Cereb Blood Flow Metab 28: 892-896.
20. Loftus LT, Gala R, Yang T, Jessick VJ, Ashley MD, et al. (2009) Sumo-2/3-ylation following in vitro modeled ischemia is reduced in delayed ischemic tolerance. Brain Res 1272: 71-80.
21. Cimarosti H, Henley JM, (2008b) Investigating the mechanisms underlying neuronal death in ischemia using in vitro oxygen-glucose deprivation: potential involvement of protein SUMOylation. Neuroscientist 14: 626-636.
22. Datwyler AL, Lattig-Tunnemann G, Yang W, Paschen W, Lee SL, et al. (2011) SUMO2/3 conjugation is an endogenous neuroprotective mechanism. J Cereb Blood Flow Metab DOI:10.1038/jcbfm.2011.112.
23. Siepmann TJ, Bohnsack RN, Tokgoz Z, Baboshina OV, Haas AL, (2003) Protein interactions within the N-end rule ubiquitin ligation pathway. J Biol Chem 278: 9448-9457.
24. Wee KE, Lai Z, Auger KR, Ma J, Horiuchi KY, et al. (2000) Steady-state kinetic analysis of human ubiquitin-activating enzyme (E1) using a fluorescently labeled ubiquitin substrate. J Protein Chem 19: 489-498.
25. Walden H, Podgorski MS, Schulman BA, (2003) Insights into the ubiquitin transfer cascade from the structure of the activating enzyme for NEDD8. Nature 422: 330-334.
26. Olsen SK, Capili AD, Lu X, Tan DS, Lima CD, (2010) Active site remodelling accompanies thioester bond formation in the SUMO E1. Nature 463: 906-912.
27. Wang J, Cai S, Chen Y, (2010) Mechanism of E1-E2 interaction for the inhibition of Ubl adenylation. J Biol Chem 285: 33457-33462.
28. Kurtzman AL, Schechter N, (2001) Ubc9 interacts with a nuclear localization signal and mediates nuclear localization of the paired-like homeobox protein Vsx-1 independent of SUMO-1 modification. Proc Natl Acad Sci U S A 98: 5602-5607.
29. Kaul S, Blackford JA Jr, Cho S, Simons SS Jr, (2002) Ubc9 is a novel modulator of the induction properties of glucocorticoid receptors. J Biol Chem 277: 12541-12549.
30. Kurihara I, Shibata H, Kobayashi S, Suda N, Ikeda Y, et al. (2005) Ubc9 and Protein Inhibitor of Activated STAT 1 Activate Chicken Ovalbumin Upstream Promoter-Transcription Factor I-mediated Human CYP11B2 Gene Transcription. J Biol Chem 280: 6721-6730.
31. Tomoiu A, Gravel A, Tanguay RM, Flamand L, (2006) Functional interaction between human herpesvirus 6 immediate-early 2 protein and ubiquitin-conjugating enzyme 9 in the absence of sumoylation. J Virol 80: 10218-10228.
32. Jaber T, Bohl CR, Lewis GL, Wood C, West JT Jr, et al. (2009) Human Ubc9 contributes to production of fully infectious human immunodeficiency virus type 1 virions. J Virol 83: 10448-10459.
33. Zhu S, Sachdeva M, Wu F, Lu Z, Mo YY, (2010) Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene 29: 1763-1772.
34. Kobayashi S, Shibata H, Yokota K, Suda N, Murai A, et al. (2004) FHL2, UBC9, and PIAS1 are novel estrogen receptor alpha-interacting proteins. Endocr Res 30: 617-621.
35. Xu J, Watkins T, Reddy A, Reddy ES, Rao VN, (2009) A novel mechanism whereby BRCA1/1a/1b fine tunes the dynamic complex interplay between SUMO-dependent/independent activities of Ubc9 on E2-induced ERalpha activation/repression and degradation in breast cancer cells. Int J Oncol 34: 939-949.
36. Geiss-Friedlander R, Melchior F, (2007) Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol 8: 947-956.
37. Golebiowski F, Matic I, Tatham MH, Cole C, Yin Y, et al. (2009) System-wide changes to SUMO modifications in response to heat shock. Sci Signal 2: ra24.
38. Novak A, Guo C, Yang W, Nagy A, Lobe CG, (2000) Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision. Genesis 28: 147-155.
39. Leach MJ, Swan JH, Eisenthal D, Dopson M, Nobbs M, (1993) BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage. Stroke 24: 1063-1067.
40. Arsenijevic D, de Bilbao F, Plamondon J, Paradis E, Vallet P, et al. (2006) Increased infarct size and lack of hyperphagic response after focal cerebral ischemia in peroxisome proliferator-activated receptor beta-deficient mice. J Cereb Blood Flow Metab 26: 433-445.